Details of Disease

General Information of Disease (ID: DISCNSWD)

• Disease Name: Palmoplantar pustulosis
• Synonyms: palmoplantar pustulosis; pustulosis of palm and sole; acropustulosis; localized pustular psoriasis; pustular psoriasis of the palms and/or soles; localised pustular psoriasis; LPP; PPP; Palmoplantar Pustulosis
• Disease Class: EA90: Psoriasis
• Disease Hierarchy:
  DISIDQ39: Epidermal disease
  DIS59VMN: Psoriasis
  DISCNSWD: Palmoplantar pustulosis
• ICD Code:
  ICD-11: ICD-11: EA90.42
  ICD-10: ICD-10: L40.3
  Expand ICD-11: 'EA90.42
  Expand ICD-10: 'L40.3
• Disease Identifiers:
  MONDO ID: MONDO_0015597
  MESH ID: D011565
  UMLS CUI: C0030246
  MedGen ID: 45290
  HPO ID: HP:0100847
  Orphanet ID: 163927
  SNOMED CT ID: 27520001

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Spesolimab	DM9FZYT	Approved	NA	[1]

This Disease is Treated as An Indication in 1 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
RIST4721	DMA3DKO	Phase 2	Small molecule	[2]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 24 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
HCAR2	TTWNV8U	Limited	Biomarker	[3]
APOE	TTKS9CB	Strong	Genetic Variation	[4]
CARM1	TTIZQFJ	Strong	Biomarker	[5]
CAT	TTPS279	Strong	Biomarker	[6]
CSF2	TTNYZG2	Strong	Biomarker	[7]
DDX58	TTVB0O3	Strong	Biomarker	[5]
ERAP1	TT60XFL	Strong	Biomarker	[8]
GJB2	TTRGZX3	Strong	Biomarker	[8]
IL12B	TTGW72V	Strong	Biomarker	[9]
IL13	TT0GVCH	Strong	Biomarker	[9]
IL23R	TT6H4QR	Strong	Biomarker	[8]
IL4	TTLGTKB	Strong	Biomarker	[10]
MKI67	TTB4UNG	Strong	Biomarker	[11]
NFKBIA	TTSHAEB	Strong	Biomarker	[9]
PCNA	TTLG1PD	Strong	Biomarker	[11]
PPARG	TTT2SVW	Strong	Therapeutic	[12]
REL	TT1ZCTH	Strong	Biomarker	[9]
REN	TTB2MXP	Strong	Biomarker	[13]
RUNX3	TTKCVO7	Strong	Biomarker	[5]
TGFA	TTTLQFR	Strong	Biomarker	[14]
TNFAIP3	TT5W0IO	Strong	Biomarker	[9]
TYK2	TTBYWP2	Strong	Biomarker	[9]
CRP	TTWRN6M	Definitive	Biomarker	[15]
IL23A	TTC1GLB	Definitive	Biomarker	[16]

This Disease Is Related to 1 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
CYP2S1	DE6NMGO	Limited	Biomarker	[17]

This Disease Is Related to 19 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
AP1S3	OTPCMV24	Supportive	Autosomal dominant	[18]
IL36RN	OT5CO95A	Supportive	Autosomal dominant	[19]
CP	OTM8JE4Y	Strong	Biomarker	[6]
CSMD1	OTIVDSC4	Strong	Biomarker	[20]
FBXL19	OTGDHPOE	Strong	Biomarker	[21]
IFIH1	OTZA2AHA	Strong	Biomarker	[9]
IFNLR1	OTWWWK45	Strong	Biomarker	[9]
LCE3B	OT7X6LDK	Strong	Biomarker	[22]
LCE3C	OT3RWMGH	Strong	Biomarker	[22]
LCE3D	OTNAIJSE	Strong	Biomarker	[8]
PTTG1	OTIMYS4W	Strong	Biomarker	[20]
RNF114	OTF06FRP	Strong	Biomarker	[9]
S100A7	OTJFVJRF	Strong	Biomarker	[23]
SERPINB8	OT5T4Y5R	Strong	Biomarker	[20]
TAGAP	OTHJNNO2	Strong	Biomarker	[5]
TNIP1	OTRAOTEW	Strong	Biomarker	[9]
TRAF3IP2	OTLLZERL	Strong	Biomarker	[24]
CARD14	OTADQHOV	Definitive	Biomarker	[25]
HLA-C	OTV38BUJ	Definitive	Biomarker	[9]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] ClinicalTrials.gov (NCT05194839) A Randomized, Double-blind, Placebo-controlled, Dose Ranging Phase 2 Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects With Palmoplantar Pustulosis. U.S.National Institutes of Health.
• [3] The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist. Biochem Biophys Res Commun. 2008 Oct 31;375(4):562-5.
• [4] Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. Br J Dermatol. 2006 Feb;154(2):345-52. doi: 10.1111/j.1365-2133.2005.06950.x.
• [5] Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity.Nat Genet. 2012 Dec;44(12):1341-8. doi: 10.1038/ng.2467. Epub 2012 Nov 11.
• [6] Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant-antioxidant system in patients with psoriasis.Clin Chim Acta. 2003 Feb;328(1-2):71-82. doi: 10.1016/s0009-8981(02)00373-x.
• [7] Increased mRNA expression of manganese superoxide dismutase in psoriasis skin lesions and in cultured human keratinocytes exposed to IL-1 beta and TNF-alpha.Free Radic Biol Med. 1995 Feb;18(2):349-55. doi: 10.1016/0891-5849(94)e0124-2.
• [8] A large-scale screen for coding variants predisposing to psoriasis.Nat Genet. 2014 Jan;46(1):45-50. doi: 10.1038/ng.2827. Epub 2013 Nov 10.
• [9] A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1.Nat Genet. 2010 Nov;42(11):985-90. doi: 10.1038/ng.694. Epub 2010 Oct 17.
• [10] Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways.Nat Genet. 2009 Feb;41(2):199-204. doi: 10.1038/ng.311. Epub 2009 Jan 25.
• [11] Expression of p53 protein before and after PUVA treatment in psoriasis.Acta Derm Venereol. 1999 May;79(3):195-9. doi: 10.1080/000155599750010959.
• [12] Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation.Arch Dermatol. 2000 May;136(5):609-16. doi: 10.1001/archderm.136.5.609.
• [13] Captopril-induced proteinuria in hypertensive psoriatic patients.Nephron. 1986;44(4):358-60. doi: 10.1159/000184020.
• [14] Localization of transforming growth factor-alpha RNA and protein in the skin of psoriatic patients receiving therapy.Br J Dermatol. 1994 Jul;131(1):64-71. doi: 10.1111/j.1365-2133.1994.tb08459.x.
• [15] Long-term remarkable remission of SAPHO syndrome in response to short-term systemic corticosteroids treatment in an immunoglobulin E elevated patient: A case report.Medicine (Baltimore). 2019 Jul;98(27):e16045. doi: 10.1097/MD.0000000000016045.
• [16] Palmoplantar pustular psoriasis (PPPP) is characterized by activation of the IL-17A pathway.J Dermatol Sci. 2017 Jan;85(1):20-26. doi: 10.1016/j.jdermsci.2016.09.019. Epub 2016 Sep 29.
• [17] Cutaneous expression of cytochrome P450 CYP2S1: individuality in regulation by therapeutic agents for psoriasis and other skin diseases. Lancet. 2003 Apr 19;361(9366):1336-43.
• [18] AP1S3 mutations are associated with pustular psoriasis and impaired Toll-like receptor 3 trafficking. Am J Hum Genet. 2014 May 1;94(5):790-7. doi: 10.1016/j.ajhg.2014.04.005.
• [19] Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes. J Invest Dermatol. 2013 May;133(5):1366-9. doi: 10.1038/jid.2012.490. Epub 2013 Jan 10.
• [20] Association analyses identify six new psoriasis susceptibility loci in the Chinese population.Nat Genet. 2010 Nov;42(11):1005-9. doi: 10.1038/ng.690. Epub 2010 Oct 17.
• [21] Genome-wide association analysis identifies three psoriasis susceptibility loci.Nat Genet. 2010 Nov;42(11):1000-4. doi: 10.1038/ng.693. Epub 2010 Oct 17.
• [22] Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis.Nat Genet. 2009 Feb;41(2):211-5. doi: 10.1038/ng.313. Epub 2009 Jan 25.
• [23] Microbicidal protein psoriasin is a multifunctional modulator of neutrophil activation.Immunology. 2008 Jul;124(3):357-67. doi: 10.1111/j.1365-2567.2007.02782.x. Epub 2008 Jan 8.
• [24] Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis.Nat Genet. 2010 Nov;42(11):996-9. doi: 10.1038/ng.688. Epub 2010 Oct 17.
• [25] Autoinflammatory keratinization diseases: An emerging concept encompassing various inflammatory keratinization disorders of the skin.J Dermatol Sci. 2018 May;90(2):105-111. doi: 10.1016/j.jdermsci.2018.01.012. Epub 2018 Feb 1.